drugset / Trial / NCT04023760
Drug Interaction Study of Apixaban With Cyclosporine or Tacrolimus in Transplant Recipients
Phase 4
Completed
14 enrolled
University of Saskatchewan
Lung Association of Saskatchewan · collabSaskatchewan Health Research Foundation · collab
Non-randomizedParallel-groupOpen-labelOther
Summary
This study aims to evaluate the pharmacokinetics (PK) of apixaban in kidney and lung transplant recipients stabilized on either cyclosporine or tacrolimus as part of their immunosuppressive therapy.
Timeline
- Start
- 2019-06-26
- Primary completion
- 2020-03-30
- Completion
- 2020-03-30
Publications
- Background Bashir B, Stickle DF, Chervoneva I, Kraft WK. Drug-Drug Interaction Study of Apixaban with Cyclosporine and Tacrolimus in Healthy Volunteers. Clin Transl Sci. 2018 Nov;11(6):590-596. doi: 10.1111/cts.12580. Epub 2018 Jul 27.
- Mansell H, Shoker A, Alcorn J, Fenton ME, Tam JS, Semchuk W, Bashir B, Kraft WK, Yao S, Douketis JD. Pharmacokinetics of apixaban and tacrolimus or cyclosporine in kidney and lung transplant recipients. Clin Transl Sci. 2022 Jul;15(7):1687-1697. doi: 10.1111/cts.13284. Epub 2022 May 2.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apixaban | Small molecule | 10 mg | Oral |
Indications
No indication recorded.